Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Assets (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Assets for 12 consecutive years, with $288.4 million as the latest value for Q1 2026.

  • For Q1 2026, Assets fell 29.51% year-over-year to $288.4 million; the TTM value through Mar 2026 reached $288.4 million, down 29.51%, while the annual FY2025 figure was $296.4 million, 31.86% down from the prior year.
  • Assets hit $288.4 million in Q1 2026 for Cartesian Therapeutics, down from $296.4 million in the prior quarter.
  • Across five years, Assets topped out at $455.3 million in Q3 2024 and bottomed at $106.0 million in Q3 2023.
  • Average Assets over 5 years is $276.6 million, with a median of $296.4 million recorded in 2025.
  • Year-over-year, Assets tumbled 40.52% in 2023 and then surged 329.41% in 2024.
  • Cartesian Therapeutics' Assets stood at $165.9 million in 2022, then skyrocketed by 83.89% to $305.0 million in 2023, then soared by 42.61% to $435.0 million in 2024, then crashed by 31.86% to $296.4 million in 2025, then fell by 2.71% to $288.4 million in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $288.4 million, $296.4 million, and $372.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.